Non-Hodgkin Lymphoma

Preliminary Phase II Trial Data Of Antibody Therapy Released

Published in Cancer Weekly, January 22nd, 2002

Protein Design Labs, Inc., (PDL) announced partial, preliminary data from its Phase II trial of Remitogen (Smart 1D10), a humanized antibody being evaluated in patients with relapsed or refractory low-grade or follicular non-Hodgkin lymphoma.

The data were reported December 10, 2001, by Brian K. Link, MD, assistant professor of internal medicine, University of Iowa, at a poster presentation at the 43rd Annual Meeting of the American Society of Hematology in Orlando, Florida.

The multicenter, open-label, two-arm, randomized study in 60 patients began in February 2001 and is evaluating the safety, overall response rate and response duration of two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-01-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry